Sun et al., 2014 - Google Patents
A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomasSun et al., 2014
- Document ID
- 641215540040498688
- Author
- Sun J
- Cai L
- Zhang K
- Zhang A
- Pu P
- Yang W
- Gao S
- Publication year
- Publication venue
- Clinical Nuclear Medicine
External Links
Snippet
Abstract 11 C-PD153035, a potent and specific ATP-competitive tyrosine kinase inhibitor (TKI) of the EGF receptor, has been developed for PET imaging of epidermal growth factor receptor (EGFR) in lung cancer. The objective of the present study was to investigate the …
- 238000003384 imaging method 0 title abstract description 39
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Autio et al. | Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial | |
Kikuchi et al. | Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma | |
Sun et al. | A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas | |
Nishio et al. | Optimal dosing strategy for fluorescence-guided surgery with panitumumab-IRDye800CW in head and neck cancer | |
Kato et al. | Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity | |
Jansen et al. | Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma | |
Bandopadhayay et al. | Long‐term outcome of 4,040 children diagnosed with pediatric low‐grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database | |
Stacchiotti et al. | Phase II study of imatinib in advanced chordoma | |
Kunz et al. | Hot spots in dynamic18FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas | |
Yamamoto et al. | Correlation of 18F-FLT uptake with tumor grade and Ki-67 immunohistochemistry in patients with newly diagnosed and recurrent gliomas | |
US20220001043A1 (en) | Cd8 imaging constructs and methods of use thereof | |
Enslow et al. | Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma | |
Baker et al. | Comparison of [99m Tc] tilmanocept and filtered [99m Tc] sulfur colloid for identification of SLNs in breast cancer patients | |
Zinnhardt et al. | TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma | |
Saito et al. | 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors | |
Qiao et al. | Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma | |
Krishnan et al. | Identifying CD38+ cells in patients with multiple myeloma: First-in-human imaging using copper-64–labeled daratumumab | |
Shinomiya et al. | Evaluation of 3′-deoxy-3′-[18 F]-fluorothymidine (18 F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas | |
Kamson et al. | Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma | |
van Dijk et al. | PET imaging in head and neck cancer patients to monitor treatment response: a future role for EGFR-targeted imaging | |
Henry et al. | Noninvasive 89Zr-transferrin PET shows improved tumor targeting compared with 18F-FDG PET in MYC-overexpressing human triple-negative breast cancer | |
Ortega et al. | Treatment and survival of patients harboring histological variants of glioblastoma | |
Badr et al. | Predictive value of FDG PET/CT versus bone marrow biopsy in pediatric lymphoma | |
Mix et al. | Performance of 111 In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy | |
Chang et al. | SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma |